
TSHA Stock Forecast & Price Target
TSHA Analyst Ratings
Bulls say
Taysha Gene Therapies is viewed positively because TSHA-102 is showing unusually strong early efficacy in Rett syndrome, with an 83% response rate at six months and 100% at 12 months across 12 initial patients, plus 31 developmental milestones and 310 total functional gains. The data also look durable and differentiated, with broad improvements in communication, sleep, seizures, and motor skills, while safety remains clean across 29 treated patients with no treatment-related SAEs or DLTs. Fundamentally, the company benefits from a validated AAV9 platform and a pivotal trial that is fully overenrolled at 17 patients, supporting a favorable setup ahead of pivotal data in 1H27.
Bears say
Taysha Gene Therapies is viewed negatively because its lead CNS gene therapy assets remain exposed to substantial clinical failure risk, including the possibility that TSHA-102 does not show enough efficacy or a tolerable safety profile, with AAV programs also facing known concerns such as severe immunological responses and DRG toxicity. Regulatory uncertainty adds another layer of risk, since none of its drugs are approved by the FDA or EMA and intrathecal gene therapy may draw increased scrutiny, while commercialization would require building its own sales force and market presence. Financially, the company is likely to need additional equity financing to advance development, which raises dilution risk, and it faces a crowded Rett syndrome landscape with approved Daybue in March 2023, Anavex data, and Neurogene’s Phase I program.
This aggregate rating is based on analysts' research of Taysha Gene Therapies and is not a guaranteed prediction by Public.com or investment advice.
TSHA Analyst Forecast & Price Prediction
Start investing in TSHA
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Taysha Gene Therapies (TSHA) Forecast
TSHA Analyst Forecast & Price Prediction
Start investing in TSHA
Order type
Buy in
Order amount
Est. shares
0 shares